Results 221 to 230 of about 432,485 (265)
Abstract We reviewed the current status and perspectives on salvage esophagectomy for initially unresectable locally advanced esophageal squamous cell carcinoma (ESCC) in the era of minimally invasive surgery and immunotherapy. Although the standard treatment for these patients is definitive chemoradiotherapy (CRT), the complete response rate to CRT ...
Hiroshi Saeki+4 more
wiley +1 more source
A tumour-associated antigen from the pleural effusion of patients with squamous-cell carcinoma of lung [PDF]
A.P. Wolf
openalex +1 more source
Adequate contact between the intubation tube and the vocal cord muscles is crucial for effective intraoperative nerve monitoring use during esophagectomy. Additionally, intraoperative posture significantly affects diagnostic outcomes and should be carefully considered.
Masami Yuda+9 more
wiley +1 more source
The association between BMD reduction during NAC and the worse prognosis remains unknown, although NAC followed by esophagectomy is a standard treatment for advanced ESCC. This study appeared that BMD massive reduction was an independent prognostic factor on OS (HR, 3.30; 95% confidence interval [CI], 1.69–6.55) and RFS (HR, 2.08; 95% CI, 1.19–3.63 ...
Kazuhide Sato+11 more
wiley +1 more source
A Case of Squamous-Cell Carcinoma developing in the Chronic Sinuses of Osteomyelitis
K. Hirata, R. Hoki
openalex +2 more sources
This multicenter study investigated 14 152 minimally invasive esophagectomies (MIEs) using data from the Japanese National Clinical Database and showed a significantly lower operative mortality rate in high‐volume centers than in low‐volume centers. However, no differences in morbidity rates were found between facility sizes.
Taro Oshikiri+4 more
wiley +1 more source
This study aimed to investigate survival outcomes, the efficacy of lymph node (LN) dissection, and recurrence patterns in 69 patients who underwent R0 salvage surgery for esophageal squamous cell carcinoma. Of note, abdominal LN metastases had a negative impact on survival in our series.
Kotaro Sugawara+9 more
wiley +1 more source
This multi‐institutional, randomized, phase II trial aimed to investigate the long‐term survival outcomes of two versus three courses of DCF for locally advanced esophageal squamous cell carcinoma (ESCC). The 5‐year overall survival and progression‐free survival rates for the three and two course groups were 70.7% vs. 63.8% (hazard ratio (HR) = 0.91, p
Takahito Sugase+19 more
wiley +1 more source
This study introduces an immunomodulatory DNA tetrahedral framework nucleic acid‐based nanovaccine tFNA‐CpG. The functionalized nanovaccine shows stable and well‐defined morphological characteristics and can be efficiently taken up by APCs. When combined with the immune checkpoint inhibitor anti‐PD‐1, it notably ameliorated the immunosuppressive ...
Xueting Yang+12 more
wiley +1 more source